DocGo Boosts 2026 Revenue Outlook, Core Business Up 19% After Q1 Beat
DCGO sits 32% above its 52-week low of $0.491.
Summary
DocGo Inc. reported mixed first-quarter results but provided a significantly more optimistic outlook for 2026, which is highly material given its recent "going concern" warning. The company beat Q1 revenue expectations with $75.60 million, despite an overall year-over-year decline entirely attributed to the wind-down of migrant-related programs. Crucially, excluding these programs, core revenue grew 19% year-over-year. Management raised its 2026 revenue guidance to $300-$315 million (from $290-$310 million) and expects adjusted EBITDA profitability in the second half of 2026, which directly addresses the financial stability concerns raised in its last 10-K. While Q1 adjusted EBITDA missed consensus, the strong underlying business growth and improved forward guidance suggest a potential inflection point for the micro-cap company. Investors will now watch for consistent execution on the path to profitability and continued core business expansion.
At the time of this announcement, DCGO was trading at $0.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.5M. The 52-week trading range was $0.49 to $1.93. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.